Example A225 [WO2012170976A2]   Click here for help

GtoPdb Ligand ID: 11983

Synonyms: TL-895 | TL895
Compound class: Synthetic organic
Comment: Example A225 [WO2012170976A2] is an investigational Bruton's tyrosine kinase (BTK) inhibitor. It is a fluoropiperidin analogue of evobrutinib and its chemical structure is claimed in Merck patent. This compound has been identified as TL-895 by online chemical resources, in which it is described as an orally-available, selective and irreversible BTK inhibitor. TL-895 was originally developed for potential to treat refractory myelofibrosis and acute myeloid leukemia (AML).

COVID-19: TL-895 has been redeployed for anti-inflammatory potential in COVID-19 patients. BTK inhibition is expected to reduce production of pro-inflammatory cytokines that are associated with cytokine storm, disease progression and poor prognosis in hospitalised COVID-19 patients.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 93.37
Molecular weight 447.21
XLogP 4.35
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C=CC(=O)N1CCC(CC1)(F)CNc1ncnc(c1c1ccc(cc1)Oc1ccccc1)N
Isomeric SMILES C=CC(=O)N1CCC(CC1)(CNc1ncnc(c1c1ccc(cc1)Oc1ccccc1)N)F
InChI InChI=1S/C25H26FN5O2/c1-2-21(32)31-14-12-25(26,13-15-31)16-28-24-22(23(27)29-17-30-24)18-8-10-20(11-9-18)33-19-6-4-3-5-7-19/h2-11,17H,1,12-16H2,(H3,27,28,29,30)
InChI Key OXOXFDSEGFLWLU-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
TL-895 is being evaluated for immunosuppressive potential in myeloproliferative diseases and SARS-CoV-2 infection (COVID-19).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04878003 Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis Phase 2 Interventional Kartos Therapeutics, Inc.
NCT04669067 TL-895 and KRT-232 Study in Acute Myeloid Leukemia Phase 1/Phase 2 Interventional Telios Pharma, Inc.
NCT04419623 A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer Phase 1 Interventional Telios Pharma, Inc.